

# Preference-Based EQ-5D Index Scores for Chronic Conc

Medical Decision Making

26, 410-420

DOI: 10.1177/0272989x06290495

Citation Report

#	ARTICLE	IF	CITATIONS
1	Acquired dysarthria in childhood. <i>Neurology</i> , 1987, 37, 296-296.	1.5	13
2	The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US. <i>Pharmacoeconomics</i> , 2006, 24, 1021-1033.	1.7	132
3	Mapping the EQ-5D Index from the SF-12: US General Population Preferences in a Nationally Representative Sample. <i>Medical Decision Making</i> , 2006, 26, 401-409.	1.2	162
6	Health Status and Health-Related Quality of Life Preference-Based Outcomes of Children Who Are Aged 7 to 9 Years and Have Bilateral Permanent Childhood Hearing Impairment. <i>Pediatrics</i> , 2007, 120, 1044-1052.	1.0	31
7	US Norms for Six Generic Health-Related Quality-of-Life Indexes From the National Health Measurement Study. <i>Medical Care</i> , 2007, 45, 1162-1170.	1.1	391
8	Measuring Preferences for Cost-Utility Analysis. <i>Pharmacoeconomics</i> , 2007, 25, 93-106.	1.7	89
9	The Economic Burden of Chronic Cardiovascular Disease for Major Insurers. <i>Health Promotion Practice</i> , 2007, 8, 234-242.	0.9	114
10	Current Assessment of Risk-Benefit by Regulators: Is It Time to Introduce Decision Analyses?. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 123-127.	2.3	37
11	The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. <i>Quality of Life Research</i> , 2008, 17, 1063-1071.	1.5	97
12	Personality and EQ-5D scores among individuals with chronic conditions. <i>Quality of Life Research</i> , 2008, 17, 1195-1204.	1.5	17
13	To Resurface or Not to Resurface the Patella in Total Knee Arthroplasty. <i>Clinical Orthopaedics and Related Research</i> , 2008, 466, 2775-2783.	0.7	68
14	Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). <i>European Journal of Pain</i> , 2008, 12, 1047-1058.	1.4	185
15	Quality of Life Utilities for Pelvic Inflammatory Disease Health States. <i>Sexually Transmitted Diseases</i> , 2008, 35, 307-311.	0.8	33
16	Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. <i>Heart</i> , 2008, 95, 542-549.	1.2	72
17	The Impact of Prevention on Reducing the Burden of Cardiovascular Disease. <i>Diabetes Care</i> , 2008, 31, 1686-1696.	4.3	75
18	The Potential Effects Of HEDIS Performance Measures On The Quality Of Care. <i>Health Affairs</i> , 2008, 27, 1429-1441.	2.5	23
19	The Impact of Prevention on Reducing the Burden of Cardiovascular Disease. <i>Circulation</i> , 2008, 118, 576-585.	1.6	228
20	Spinal cord stimulation for failed back surgery syndrome—does it work and is it cost-effective?. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 472-473.	2.7	1

#	ARTICLE	IF	CITATIONS
21	Economic Evaluation of the US Environmental Protection Agency's SunWise Program: Sun Protection Education for Young Children. <i>Pediatrics</i> , 2008, 121, e1074-e1084.	1.0	73
22	Utilities Should Not Be Multiplied. <i>Medical Care</i> , 2008, 46, 984-990.	1.1	44
23	Cost-effectiveness of insulin analogues for diabetes mellitus. <i>Cmaj</i> , 2009, 180, 400-407.	0.9	90
24	Estimating Preference-Based Health Utilities Index Mark 3 Utility Scores for Childhood Conditions in England and Scotland. <i>Medical Decision Making</i> , 2009, 29, 291-303.	1.2	64
25	Effect of Smoking Cessation Advice on Cardiovascular Disease. <i>American Journal of Medical Quality</i> , 2009, 24, 241-249.	0.2	15
26	Reimbursement agency requirements for health related quality-of-life data: a case study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 527-537.	0.7	9
27	CT Coronary Angiography in Patients Suspected of Having Coronary Artery Disease: Decision Making from Various Perspectives in the Face of Uncertainty. <i>Radiology</i> , 2009, 253, 734-744.	3.6	57
28	The cost-effectiveness of Maze procedures using ablation techniques at the time of mitral valve surgery. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 485-496.	0.2	15
29	An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 26-34.	0.2	39
30	Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. <i>Clinical Therapeutics</i> , 2009, 31, 862-879.	1.1	9
31	Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. <i>Quality of Life Research</i> , 2009, 18, 801-813.	1.5	47
32	An updated systematic review of Health State Utility Values for osteoporosis related conditions. <i>Osteoporosis International</i> , 2009, 20, 853-868.	1.3	118
33	Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic <sup>®</sup> CONTROL study. <i>British Journal of Dermatology</i> , 2009, 161, 1335-1340.	1.4	19
34	Hypoactive Sexual Desire Disorder in Postmenopausal Women: Quality of Life and Health Burden. <i>Value in Health</i> , 2009, 12, 763-772.	0.1	113
35	A Catalogue of EQ-5D Utility Weights for Chronic Diseases among Noninstitutionalized Community Residents in Korea. <i>Value in Health</i> , 2009, 12, S114-S117.	0.1	32
36	Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. <i>American Heart Journal</i> , 2009, 157, 845-852.	1.2	56
37	Cost-effectiveness of warfarin: Trial versus "real-world" stroke prevention in atrial fibrillation. <i>American Heart Journal</i> , 2009, 157, 1064-1073.	1.2	77
38	Potential Societal Savings from Reduced Sodium Consumption in the U.S. Adult Population. <i>American Journal of Health Promotion</i> , 2009, 24, 49-57.	0.9	122

#	ARTICLE	IF	CITATIONS
39	Health utility and economic analysis: theoretical and practical issues. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 289-292.	0.7	7
40	Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids. International Journal of Technology Assessment in Health Care, 2009, 25, 14-25.	0.2	57
41	Time Trends and Seasonal Patterns of Health-Related Quality of Life among U.S. Adults. Public Health Reports, 2009, 124, 692-701.	1.3	40
42	Relative Efficiency of the EQ-5D, HUI2, and HUI3 Index Scores in Measuring Health Burden of Chronic Medical Conditions in a Population Health Survey in the United States. Medical Care, 2009, 47, 53-60.	1.1	54
43	Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 2373.	3.8	232
44	Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. European Journal of Health Economics, 2010, 11, 427-434.	1.4	92
45	The Well-Being of Parental Caregivers of Children with Activity Limitations. Maternal and Child Health Journal, 2010, 14, 155-163.	0.7	111
46	Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Quality of Life Research, 2010, 19, 381-390.	1.5	54
47	Health-related quality of life, and its determinants, among older people in rural Vietnam. BMC Public Health, 2010, 10, 549.	1.2	82
48	Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. Value in Health, 2010, 13, 487-494.	0.1	120
49	Ethnic variation, epidemiological factors and quality of life impairment associated with dyspepsia in urban Malaysia. Alimentary Pharmacology and Therapeutics, 2010, 31, 1141-1151.	1.9	55
50	Cost-utility analysis of proton pump inhibitors and other gastroprotective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents. Alimentary Pharmacology and Therapeutics, 2010, 31, 1354-1364.	1.9	10
51	Predicting Utility for Joint Health States: A General Framework and a New Nonparametric Estimator. Medical Decision Making, 2010, 30, E29-E39.	1.2	35
52	Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?. Medical Decision Making, 2010, 30, 556-565.	1.2	76
53	Risk Factors Associated With Dyspepsia in a Rural Asian Population and Its Impact on Quality of Life. American Journal of Gastroenterology, 2010, 105, 904-912.	0.2	47
54	QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 293-308.	0.7	31
55	Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate- and Low-Cardiovascular-Risk Individuals for Statin Therapy. Circulation, 2010, 122, 1478-1487.	1.6	59
56	EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, and Fibromyalgia. Journal of Rheumatology, 2010, 37, 296-304.	1.0	91

#	ARTICLE	IF	CITATIONS
57	Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. <i>Current Medical Research and Opinion</i> , 2010, 26, 2485-2497.	0.9	15
58	Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. <i>Cmaj</i> , 2010, 182, 28-34.	0.9	53
59	The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. <i>Genetics in Medicine</i> , 2010, 12, 93-104.	1.1	250
60	A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 275-282.	0.6	22
61	Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada. <i>Applied Health Economics and Health Policy</i> , 2010, 8, 267-280.	1.0	18
62	Three methods tested to model SF-6D health utilities for health states involving comorbidity/co-occurring conditions. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 331-341.	2.4	20
63	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <i>Lancet, The</i> , 2010, 375, 1365-1374.	6.3	228
64	A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing. <i>Pharmacoeconomics</i> , 2010, 28, 61-74.	1.7	86
65	Cost Effectiveness of Self-Monitoring of Blood Glucose (SMBG) for Patients with Type 2 Diabetes and Not on Insulin. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 351-365.	1.0	13
66	Catalogue of EQ-5D Scores for the United Kingdom. <i>Medical Decision Making</i> , 2011, 31, 800-804.	1.2	270
67	The Burden of Fibromyalgia: Assessment of Health Status Using the EuroQol (EQ-5D) in Patients with Fibromyalgia Relative to Other Chronic Conditions. <i>Health Outcomes Research in Medicine</i> , 2011, 2, e203-e214.	0.6	7
68	Utility-Based Quality of Life of Overweight and Obese Adolescents. <i>Value in Health</i> , 2011, 14, 752-758.	0.1	16
69	Valuing the Health Impacts of Air Emissions. , 2011, , 619-627.		2
70	The Costâ€“Utility of Adjuvant Chemotherapy Using Docetaxel and Cyclophosphamide Compared with Doxorubicin and Cyclophosphamide in Breast Cancer. <i>Current Oncology</i> , 2011, 18, 288-296.	0.9	26
71	Improving the Quality of Pressure Ulcer Care With Prevention. <i>Medical Care</i> , 2011, 49, 385-392.	1.1	152
72	Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 1.	2.0	363
73	An Integrated Health-Economic Analysis of Diagnostic and Therapeutic Strategies in the Treatment of Moderate-to-Severe Obstructive Sleep Apnea. <i>Sleep</i> , 2011, 34, 695-709.	0.6	119
74	Comparison of Rate Control versus Rhythm Control for Management of Atrial Fibrillation in Patients with Coexisting Heart Failure: A Costâ€“Effectiveness Analysis. <i>Pharmacotherapy</i> , 2011, 31, 552-565.	1.2	16

#	ARTICLE	IF	CITATIONS
75	A Quality-Adjusted Life Year of Prevention: The Cost-Effectiveness of Nutrition Counseling. <i>Journal of the American Dietetic Association</i> , 2011, 111, 53-55.	1.3	2
76	Estimating Health and Economic Benefits from Using Prescription Omega-3 Fatty Acids in Patients With Severe Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2011, 108, 691-697.	0.7	13
77	EuroQol (EQ-5D) health utility scores for patients with migraine. <i>Quality of Life Research</i> , 2011, 20, 601-608.	1.5	47
78	Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. <i>Quality of Life Research</i> , 2011, 20, 939-943.	1.5	44
79	Assessment of the Construct Validity of the EQ-5D in Patients with Acute Cough/Lower Respiratory Tract Infections. <i>Applied Research in Quality of Life</i> , 2011, 6, 411-423.	1.4	7
80	Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. <i>Cost Effectiveness and Resource Allocation</i> , 2011, 9, 13.	0.6	59
81	Validity of Quality of Life Measurement Tools -- From Generic to Disease-specific. <i>Journal of rheumatology Supplement, The</i> , 2011, 88, 2-6.	2.2	52
82	The Income Elasticity of the Value per Statistical Life: Transferring Estimates between High and Low Income Populations. <i>Journal of Benefit-Cost Analysis</i> , 2011, 2, 1-29.	0.6	207
83	Are Utilities Bounded at 1.0? Implications for Statistical Analysis and Scale Development. <i>Medical Decision Making</i> , 2011, 31, 787-789.	1.2	16
84	Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. <i>Cmaj</i> , 2011, 183, E1213-E1220.	0.9	47
85	Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. <i>Journal of Medical Economics</i> , 2011, 14, 207-216.	1.0	13
86	Quality-of-Life Implications of Immediate Surgery and Watchful Waiting in Asymptomatic Aortic Stenosis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 541-548.	0.9	16
87	Predicting the EuroQol Group's EQ-5D Index from CDC's "Healthy Days" in a US Sample. <i>Medical Decision Making</i> , 2011, 31, 174-185.	1.2	37
88	Calculating Utility Decrements Associated With an Adverse Event. <i>Medical Decision Making</i> , 2011, 31, 790-799.	1.2	19
89	Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. <i>BMJ: British Medical Journal</i> , 2011, 343, d6333-d6333.	2.4	137
90	Cost-Effectiveness of Computed Tomographic Angiography Before Reoperative Coronary Artery Bypass Grafting. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 705-710.	0.9	7
91	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2012, 156, 279.	2.0	176
92	Physicians' Actions And Influence, Such As Aggressive Blood Pressure Control, Greatly Improve The Health Of Diabetes Patients. <i>Health Affairs</i> , 2012, 31, 140-149.	2.5	6

#	ARTICLE	IF	CITATIONS
93	Using Models to Predict the Future: What to Do When the Data Run Out?. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 769-771.	2.3	1
94	Quantitative Benefit-Risk Assessment Using Only Qualitative Information on Utilities. <i>Medical Decision Making</i> , 2012, 32, E1-E15.	1.2	31
95	Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2012, 43, 881-883.	1.0	92
97	Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1271-1277.	1.2	126
98	Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. <i>Journal of Medical Economics</i> , 2012, 15, 253-260.	1.0	4
99	Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2012, 110, 845-851.	0.7	120
100	The impact of Irritable Bowel Syndrome on health-related quality of life: a Singapore perspective. <i>BMC Gastroenterology</i> , 2012, 12, 104.	0.8	56
101	A Risk-Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 829-837.	2.3	24
102	Smoke Alarm Giveaway and Installation Programs. <i>American Journal of Preventive Medicine</i> , 2012, 43, 385-391.	1.6	10
103	Deriving Input Parameters for Cost-Effectiveness Modeling: Taxonomy of Data Types and Approaches to Their Statistical Synthesis. <i>Value in Health</i> , 2012, 15, 639-649.	0.1	37
104	Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health Technologies. <i>Value in Health</i> , 2012, 15, 971-974.	0.1	47
105	The Impact of Co-Morbidity Burden on Preference-Based Health-Related Quality of Life in the United States. <i>Pharmacoeconomics</i> , 2012, 30, 431-442.	1.7	25
106	Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation. <i>PLoS ONE</i> , 2012, 7, e39640.	1.1	58
107	Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. <i>PLoS ONE</i> , 2012, 7, e45176.	1.1	52
108	Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation. <i>PLoS ONE</i> , 2012, 7, e47473.	1.1	60
109	Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. <i>Vascular Health and Risk Management</i> , 2012, 8, 255.	1.0	21
110	The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. <i>Annals of Internal Medicine</i> , 2012, 156, 541.	2.0	186
111	Cost-Effectiveness Analysis of a Community Health Worker Intervention for Low-Income Hispanic Adults with Diabetes. <i>Preventing Chronic Disease</i> , 2012, 9, E140.	1.7	102

#	ARTICLE	IF	CITATIONS
112	A method for the early health technology assessment of novel biomarker measurement in primary prevention programs. <i>Statistics in Medicine</i> , 2012, 31, 2733-2744.	0.8	18
113	Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness Study in Diabetic Populations. <i>Journal of General Internal Medicine</i> , 2012, 27, 730-738.	1.3	15
114	Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1115-1123.	1.1	56
115	Markov Model for Selection of Aortic Valve Replacement Versus Transcatheter Aortic Valve Implantation (Without Replacement) in High-Risk Patients. <i>American Journal of Cardiology</i> , 2012, 109, 1326-1333.	0.7	55
116	Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients. <i>Quality of Life Research</i> , 2013, 22, 1745-1751.	1.5	32
117	An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. <i>Quality of Life Research</i> , 2013, 22, 1045-1054.	1.5	23
118	Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease. <i>Quality of Life Research</i> , 2013, 22, 1065-1072.	1.5	22
119	Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations. <i>Pharmacoeconomics</i> , 2013, 31, 643-652.	1.7	21
120	Bariatric Surgery for the Treatment of Severely Obese Patients in South Korea—Is it Cost Effective?. <i>Obesity Surgery</i> , 2013, 23, 2058-2067.	1.1	24
121	Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire Scores in Patients with Colorectal Cancer. <i>Value in Health</i> , 2013, 16, 373-384.	0.1	18
122	Association between Health-Related Quality of Life and Body Mass After Adjustable Gastric Banding: A Nonlinear Approach. <i>Value in Health</i> , 2013, 16, 823-829.	0.1	7
123	A systematic literature review of cardiovascular event utilities. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 767-790.	0.7	14
124	An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. <i>BMC Public Health</i> , 2013, 13, 729.	1.2	37
125	The English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 201-209.	1.0	36
126	Catalogue of EQ-5D Scores for Chronic Conditions in Denmark. <i>Value in Health</i> , 2013, 16, A595.	0.1	1
127	Selection for early surgery in asymptomatic mitral regurgitation: A Markov model. <i>International Journal of Cardiology</i> , 2013, 165, 266-272.	0.8	5
128	RSV vaccine in development: Assessing the potential cost-effectiveness in the Dutch elderly population. <i>Vaccine</i> , 2013, 31, 6254-6260.	1.7	19
129	Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 81-91.	1.9	62



#	ARTICLE	IF	CITATIONS
130	Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?. <i>Osteoarthritis and Cartilage</i> , 2013, 21, 655-667.	0.6	56
131	The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. <i>European Journal of Health Economics</i> , 2013, 14, 197-209.	1.4	16
132	Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 269-276.	2.3	21
133	Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2013, 44, 1676-1681.	1.0	233
134	Cost-Effectiveness of Hepatitis B Vaccination in Adults With Diagnosed Diabetes. <i>Diabetes Care</i> , 2013, 36, 63-69.	4.3	37
135	Stakeholders in Outcome Measures: Review From a Clinical Perspective. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 3426-3436.	0.7	16
136	Utility-based quality of life associated with overweight and obesity: The Australian diabetes, obesity, and lifestyle study. <i>Obesity</i> , 2013, 21, 652-655.	1.5	26
137	Impact of educational level on health-related quality of life (HRQL): results from Germany based on the EuroQol 5D (EQ-5D). <i>European Journal of Public Health</i> , 2013, 23, 45-49.	0.1	52
138	Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 29-42.	0.7	7
139	Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. <i>Journal of Medical Economics</i> , 2013, 16, 510-521.	1.0	15
140	Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?. <i>Annals of Oncology</i> , 2013, 24, 1834-1840.	0.6	12
141	Sequential Value-of-Information Assessment for Prospective Drug Safety Monitoring Using Claims Databases. <i>Medical Decision Making</i> , 2013, 33, 949-960.	1.2	4
142	Bowel dysfunction after total abdominal hysterectomy for benign conditions. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1.	0.8	3
143	Transcatheter Aortic Valve Replacement in Nonsurgical Candidates With Severe, Symptomatic Aortic Stenosis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 419-428.	0.9	48
144	Cost-effectiveness of a Genetic Test for Breast Cancer Risk. <i>Cancer Prevention Research</i> , 2013, 6, 1328-1336.	0.7	9
145	Cost-Effectiveness of Renin-Guided Treatment of Hypertension. <i>American Journal of Hypertension</i> , 2013, 26, 1303-1310.	1.0	14
146	Skills of the trade: valuing health risk reductions in benefit-cost analysis. <i>Journal of Benefit-Cost Analysis</i> , 2013, 4, 107-130.	0.6	30
147	Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 675-690.	0.7	3

#	ARTICLE	IF	CITATIONS
148	Asthma in USA: its impact on health-related quality of life. <i>Journal of Asthma</i> , 2013, 50, 891-899.	0.9	52
149	Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. <i>Cancer</i> , 2013, 119, 4299-4307.	2.0	64
150	Cost-effectiveness of a primary care intervention to treat obesity. <i>International Journal of Obesity</i> , 2013, 37, S31-S37.	1.6	27
151	Comparing Five Alternative Methods of Breast Reconstruction Surgery. <i>Plastic and Reconstructive Surgery</i> , 2013, 132, 709e-723e.	0.7	53
152	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. <i>PLoS ONE</i> , 2013, 8, e58975.	1.1	61
153	Validity of LupusQoL-China for the Assessment of Health Related Quality of Life in Chinese Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2013, 8, e63795.	1.1	33
154	A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2013, 8, e66454.	1.1	35
155	Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 437.	0.7	5
156	Construct and Criterion Validity of the Euro QoL-5D in Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2014, 9, e98883.	1.1	24
157	Cost-Effectiveness of Meningococcal Quadrivalent Conjugate Vaccination Campaign among Men Who Have Sex With Men in New York City. <i>Open Forum Infectious Diseases</i> , 2014, 1, S461-S462.	0.4	0
158	Health state utility of patients with single-level cervical degenerative disc disease: comparison of anterior cervical discectomy and fusion with cervical disc arthroplasty. <i>Journal of Neurosurgery: Spine</i> , 2014, 20, 475-479.	0.9	26
159	US Valuation of Health Outcomes Measured Using the PROMIS-29. <i>Value in Health</i> , 2014, 17, 846-853.	0.1	117
160	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	1.6	29
161	Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 6-14.	0.7	26
162	Who Needs Laboratories and Who Needs Statins?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 25-32.	0.9	23
163	Health Burden Associated with Visual Impairment in Singapore. <i>Ophthalmology</i> , 2014, 121, 1837-1842.	2.5	38
164	Cost-Effectiveness Analysis of Extended Duration Anticoagulation with Rivaroxaban to Prevent Recurrent Venous Thromboembolism. <i>Thrombosis Research</i> , 2014, 133, 743-749.	0.8	17
165	Coût-efficacité et VHCÂ: mise au point. <i>Journal Des Anti-infectieux</i> , 2014, 16, 50-63.	0.1	0

#	ARTICLE	IF	CITATIONS
166	The association between motor vehicle injuries and health-related quality of life: a longitudinal study of a population-based sample in the United States. <i>Quality of Life Research</i> , 2014, 23, 119-127.	1.5	24
167	Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2014, 29, 438-446.	1.3	45
168	That's What Friends Are For: Adolescent Peer Social Status, Health-Related Quality of Life and Healthcare Costs. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 191-201.	1.0	14
169	Association Between Glycated Hemoglobin and Health Utility for Type 1 Diabetes. <i>Patient</i> , 2014, 7, 197-205.	1.1	14
170	External costs of cadmium emissions to soil: a drawback of Phosphorus fertilizers. <i>Journal of Cleaner Production</i> , 2014, 84, 475-483.	4.6	66
171	The Community Diabetes Education (CoDE) Program. <i>American Journal of Preventive Medicine</i> , 2014, 47, 771-779.	1.6	29
172	Dynamic Medication Adherence Modeling in Primary Prevention of Cardiovascular Disease: A Markov Microsimulation Methods Application. <i>Value in Health</i> , 2014, 17, 725-731.	0.1	8
173	Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 1093-1102.	2.4	10
174	Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study. <i>Atherosclerosis</i> , 2014, 236, 154-161.	0.4	15
175	Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. <i>Lancet Psychiatry</i> , 2014, 1, 55-62.	3.7	17
176	Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 507-523.	1.0	38
177	Health-related quality of life and socioeconomic status: inequalities among adults with a chronic disease. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 58.	1.0	143
178	A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation. <i>Journal of Medical Economics</i> , 2014, 17, 599-615.	1.0	30
179	Comparing clinician- and patient-reported outcome measures after hemicraniectomy for ischemic stroke. <i>Clinical Neurology and Neurosurgery</i> , 2014, 126, 24-29.	0.6	7
180	Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 623-632.	0.6	85
181	Uncertainty in the Cost-Effectiveness of Federal Air Quality Regulations. <i>Journal of Benefit-Cost Analysis</i> , 2015, 6, 66-111.	0.6	9
183	Comparative Assessment of Different Health Utility Measures in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2015, 5, 13297.	1.6	6
184	CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 609-617.	0.7	14

#	ARTICLE	IF	CITATIONS
185	Hospital Quality and Patient Choice: An Empirical Analysis of Mitral Valve Surgery. SSRN Electronic Journal, 0, , .	0.4	7
186	Suicide Behaviors and Health-Related Quality of Life: Results from the Korean Community Health Survey of 393,073 Adults. African Journal of Psychiatry, 2015, 18, .	0.1	3
187	Long-term Cost-effectiveness of Endoscopic vs Open Vein Harvest for Coronary Artery Bypass Grafting. Journal of Cardiovascular Diseases & Diagnosis, 2015, 03, .	0.0	0
188	Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis. PLoS ONE, 2015, 10, e0127213.	1.1	24
189	The Health-Related Quality of Life for Patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS). PLoS ONE, 2015, 10, e0132421.	1.1	123
190	Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany. BioMed Research International, 2015, 2015, 1-12.	0.9	22
191	The Impact of Multimorbidity on Quality of Life Among Midlife Women: Findings from a U.S. Nationally Representative Survey. Journal of Women's Health, 2015, 24, 374-383.	1.5	22
192	Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 111-123.	0.7	6
193	Acute and chronic impact of cardiovascular events on health state utilities. BMC Health Services Research, 2015, 15, 173.	0.9	47
194	Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada. Tobacco Control, 2015, 24, 489-496.	1.8	34
195	Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 621-630.	0.9	45
196	Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. International Journal of Cardiology, 2015, 181, 417-424.	0.8	32
197	Carotid Artery Stenosis: Cost-effectiveness of Assessment of Cerebrovascular Reserve to Guide Treatment of Asymptomatic Patients. Radiology, 2015, 274, 455-463.	3.6	12
198	Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control. Pharmacoeconomics, 2015, 33, 395-408.	1.7	46
199	Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). European Journal of Health Economics, 2015, 16, 1019-1026.	1.4	54
200	Estimating Utility values for Polycythemia vera using patient-reported outcomes from the response trial and existing Mapping Algorithms. Value in Health, 2015, 18, A299-A300.	0.1	0
201	Effect of Age on Cost-Effectiveness of Unicompartmental Knee Arthroplasty Compared with Total Knee Arthroplasty in the U.S.. Journal of Bone and Joint Surgery - Series A, 2015, 97, 396-402.	1.4	67
202	Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2015, 314, 142.	3.8	205

#	ARTICLE	IF	CITATIONS
203	Evaluating the economic burden of psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 961-967.e5.	0.6	111
204	Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. <i>Annals of Internal Medicine</i> , 2015, 162, 407-419.	2.0	186
205	Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial. <i>Sleep</i> , 2015, 38, 735-744.	0.6	56
206	Cardiovascular Disease Screening By Community Health Workers Can Be Cost-Effective In Low-Resource Countries. <i>Health Affairs</i> , 2015, 34, 1538-1545.	2.5	42
207	Quality of life after en bloc resection of tumors in the mobile spine. <i>Spine Journal</i> , 2015, 15, 1728-1737.	0.6	32
208	Cost-Effectiveness of Carotid Plaque MR Imaging as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis. <i>Radiology</i> , 2015, 277, 763-772.	3.6	22
209	Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. <i>Pharmacogenomics</i> , 2015, 16, 1089-1100.	0.6	13
210	Cost-Effectiveness of a Community-Based Weight Control Intervention Targeting a Low-Socioeconomic-Status Mexican-Origin Population. <i>Health Promotion Practice</i> , 2015, 16, 101-108.	0.9	14
211	Quality of Life and Visual Efficiency: fifth Korea National Health and Nutrition Examination Survey. <i>Journal of Korean Ophthalmological Society</i> , 2016, 57, 485.	0.0	4
212	Periodic limb movements of sleep: empirical and theoretical evidence supporting objective at-home monitoring. <i>Nature and Science of Sleep</i> , 2016, Volume 8, 277-289.	1.4	10
213	Medical costs and quality-adjusted life years associated with smoking: a systematic review. <i>BMC Public Health</i> , 2016, 16, 646.	1.2	14
214	Study protocol for a cluster randomized controlled trial to evaluate a referral strategy for axial spondyloarthritis in young primary care patients with chronic low back pain; an impact study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 278.	0.8	4
215	Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. <i>Pharmacotherapy</i> , 2016, 36, 488-495.	1.2	14
216	Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 146-154.	0.9	8
217	Costs of Health Damage from Atmospheric Emissions of Toxic Metals: Part 1—Methods and Results. <i>Risk Analysis</i> , 2016, 36, 2081-2095.	1.5	9
218	Valuing Health Outcomes. , 2016, , 167-200.		7
219	Health utility indexes in patients with acute coronary syndromes. <i>Open Heart</i> , 2016, 3, e000419.	0.9	14
220	Effect of Workplace Weight Management on Health Care Expenditures and Quality of Life. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, 1073-1078.	0.9	7

#	ARTICLE	IF	CITATIONS
221	Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 167.	0.7	14
222	Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 251.	0.7	3
223	Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. <i>Pharmacogenomics</i> , 2016, 17, 701-713.	0.6	28
224	Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. <i>European Respiratory Journal</i> , 2016, 47, 1697-1705.	3.1	30
225	Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 11-18.	0.4	49
226	Can skin disease cause neuropathic pain? A study in pachyonychia congenita. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 26-33.	0.6	22
227	Ayurvedic herbal preparations for hypercholesterolaemia. <i>The Cochrane Library</i> , 2016, , .	1.5	1
228	Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac. <i>Clinical Therapeutics</i> , 2016, 38, 2418-2429.	1.1	2
229	Cost-effectiveness of Intensive Blood Pressure Management. <i>JAMA Cardiology</i> , 2016, 1, 872.	3.0	48
230	EQ-5D Scores for Diabetes-Related Comorbidities. <i>Value in Health</i> , 2016, 19, 1002-1008.	0.1	67
231	Burden of allergic respiratory disease: a systematic review. <i>Clinical and Molecular Allergy</i> , 2016, 14, 12.	0.8	89
232	Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2016, 164, 777.	2.0	80
233	Burden of Visual Impairment and Chronic Diseases. <i>JAMA Ophthalmology</i> , 2016, 134, 778.	1.4	37
234	Factors affecting quality of life in patients on haemodialysis: a cross-sectional study from Palestine. <i>BMC Nephrology</i> , 2016, 17, 44.	0.8	72
235	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	17
236	Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the "Optimal" Oral Anticoagulant for Atrial Fibrillation. <i>Value in Health</i> , 2016, 19, 661-669.	0.1	3
237	Catalog of 199 register-based definitions of chronic conditions. <i>Scandinavian Journal of Public Health</i> , 2016, 44, 462-479.	1.2	40
238	Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 366-377.	1.3	16

#	ARTICLE	IF	CITATIONS
239	Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2016, 31, 394-401.	1.3	105
240	Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 491-498.	0.6	251
241	Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. <i>Osteoarthritis and Cartilage</i> , 2016, 24, 409-418.	0.6	56
242	Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. <i>Journal of Human Hypertension</i> , 2016, 30, 191-196.	1.0	16
243	Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. <i>Journal of Medical Economics</i> , 2016, 19, 191-202.	1.0	20
244	Preference-based health-related quality of life among victims of bullying. <i>Quality of Life Research</i> , 2016, 25, 303-309.	1.5	14
245	Leveraging Health-Related Quality of Life in Population Health Management: The Case for Healthy Days. <i>Population Health Management</i> , 2017, 20, 13-22.	0.8	73
246	Associations with health-related quality of life after intracerebral haemorrhage: pooled analysis of INTERACT studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 70-75.	0.9	21
247	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 657-667.	1.0	17
248	Are Evidence Standards Different for Genomic vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 805-814.	2.3	7
249	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. <i>CMAJ Open</i> , 2017, 5, E97-E108.	1.1	20
250	Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 1-3.	1.3	0
251	Application of minimal important differences in degenerative knee disease outcomes: a systematic review and case study to inform <i>BMJ</i> Rapid Recommendations. <i>BMJ Open</i> , 2017, 7, e015587.	0.8	79
252	Extending the Multiregional Input-Output Framework to Labor-Related Impacts: A Proof of Concept. <i>Journal of Industrial Ecology</i> , 2017, 21, 1536-1546.	2.8	16
253	Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. <i>Medical Decision Making</i> , 2017, 37, 802-814.	1.2	24
254	Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1223-1232.	0.5	8
255	Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. <i>Journal of Hypertension</i> , 2017, 35, 178-187.	0.3	26
256	Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. <i>Journal of Medical Economics</i> , 2017, 20, 911-922.	1.0	21

#	ARTICLE	IF	CITATIONS
257	State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. <i>Current Medical Research and Opinion</i> , 2017, 33, 1535-1543.	0.9	2
258	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.	3.0	18
259	CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 39-49.	1.3	27
260	The epidemiology and functional outcomes of operative fixation of extracapsular proximal femoral fractures (AO 31-A) in young adults. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2017, 27, 267-272.	0.6	5
261	Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. <i>Clinical Drug Investigation</i> , 2017, 37, 285-293.	1.1	14
262	A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns. <i>Headache</i> , 2017, 57, 1532-1544.	1.8	86
263	Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers. <i>JAMA Cardiology</i> , 2017, 2, 1369.	3.0	84
264	Differential item functioning in quality of life measurement: An analysis using anchoring vignettes. <i>Social Science and Medicine</i> , 2017, 190, 247-255.	1.8	15
265	Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2017, 377, 745-755.	13.9	157
266	Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?. <i>Annals of Pharmacotherapy</i> , 2017, 51, 961-969.	0.9	3
267	The Health Impact of Adult Cervical Deformity in Patients Presenting for Surgical Treatment: Comparison to United States Population Norms and Chronic Disease States Based on the EuroQuol-5 Dimensions Questionnaire. <i>Neurosurgery</i> , 2017, 80, 716-725.	0.6	74
268	Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. <i>Clinical Cardiology</i> , 2017, 40, 789-796.	0.7	5
269	Impact of health utility after thrombotic complications following total hip and knee arthroplasty. <i>ANZ Journal of Surgery</i> , 2017, 87, 820-824.	0.3	0
270	Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 938-952.	2.3	83
271	Using Economic Evaluation to Illustrate Value of Care for Improving Patient Safety and Quality: Choosing the Right Method. <i>Journal of Patient Safety</i> , 2021, 17, e568-e574.	0.7	2
272	Health-related quality of life variations by sociodemographic factors and chronic conditions in three metropolitan cities of South Asia: the CARRS study. <i>BMJ Open</i> , 2017, 7, e018424.	0.8	35
273	Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety. <i>Pharmacoeconomics</i> , 2017, 35, 1297-1310.	1.7	10
274	Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation. <i>Value in Health</i> , 2017, 20, 1329-1335.	0.1	10



#	ARTICLE	IF	CITATIONS
275	Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 18.	3.0	19
276	Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3725-3731.	2.0	66
277	Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. <i>Journal of Medical Economics</i> , 2017, 20, 288-296.	1.0	6
278	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. <i>Thrombosis Research</i> , 2017, 150, 123-130.	0.8	22
279	Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity. <i>JAMA Surgery</i> , 2017, 152, 136.	2.2	62
280	Health-related quality of life associated with systemic corticosteroids. <i>Quality of Life Research</i> , 2017, 26, 1037-1058.	1.5	14
281	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 498-506.	1.3	28
282	Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients. <i>Journal of Medical Economics</i> , 2017, 20, 82-90.	1.0	20
283	The Cost-Effectiveness of Anterior Cruciate Ligament Reconstruction in Competitive Athletes. <i>American Journal of Sports Medicine</i> , 2017, 45, 23-33.	1.9	43
284	EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre. <i>Patient</i> , 2017, 10, 105-115.	1.1	23
285	Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. <i>European Journal of Health Economics</i> , 2017, 18, 731-742.	1.4	6
286	Does the choice of tariff matter?. <i>Medicine (United States)</i> , 2017, 96, e7840.	0.4	18
287	Obesity in Mexico: prevalence, comorbidities, associations with patient outcomes, and treatment experiences. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 1-10.	1.1	41
288	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.4	14
289	The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 213.	0.7	20
290	Radiographic knee osteoarthritis impacts multiple dimensions of health-related quality of life: data from the Osteoarthritis Initiative. <i>Rheumatology</i> , 2018, 57, 891-899.	0.9	15
291	Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation. <i>Osteoarthritis and Cartilage</i> , 2018, 26, 641-650.	0.6	22
292	Comparison Between Image-Guided and Landmark-Based Glenohumeral Joint Injections for the Treatment of Adhesive Capsulitis: A Cost-Effectiveness Study. <i>American Journal of Roentgenology</i> , 2018, 210, 1279-1287.	1.0	15

#	ARTICLE	IF	CITATIONS
293	Team-Based Care with Pharmacists to Improve Blood Pressure: a Review of Recent Literature. <i>Current Hypertension Reports</i> , 2018, 20, 1.	1.5	66
294	The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx267.	0.4	7
295	Development and validation of a new population-based simulation model of osteoarthritis in New Zealand. <i>Osteoarthritis and Cartilage</i> , 2018, 26, 531-539.	0.6	6
296	Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. <i>Clinical Infectious Diseases</i> , 2018, 67, 549-556.	2.9	53
297	Evaluating health-related quality of life impact of chronic conditions among older adults from a rural town in Suzhou, China. <i>Archives of Gerontology and Geriatrics</i> , 2018, 76, 6-11.	1.4	19
298	Care Management to Reduce Disparities and Control Hypertension in Primary Care. <i>Medical Care</i> , 2018, 56, 179-185.	1.1	6
299	Utility-Based Instruments for People with Dementia: A Systematic Review and Meta-Regression Analysis. <i>Value in Health</i> , 2018, 21, 471-481.	0.1	23
301	Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005768.	1.4	10
302	Alzheimer's disease Archimedes conditionâ€event simulator: Development and validation. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 76-88.	1.8	18
303	Text Messaging to Improve Disease Management in Patients With Painful Diabetic Peripheral Neuropathy. <i>The Diabetes Educator</i> , 2018, 44, 237-248.	2.6	11
304	Oral corticosteroid exposure and adverse effects in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 110-116.e7.	1.5	211
305	Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with diseaseâ€modifying antiâ€rheumatic drugs for at least 6 months. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1001-1009.	0.9	5
306	Cost-effectiveness of magnetic resonance carotid plaque imaging for primary stroke prevention in Canada. <i>British Journal of Radiology</i> , 2018, 91, 20170518.	1.0	2
307	Approach to asymptomatic paraesophageal hernia: watchful waiting or elective laparoscopic hernia repair?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 864-871.	1.3	25
308	The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2018, 37, 151-160.	1.0	12
309	Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1671-1681.e11.	0.4	20
310	Less is more: cost-effectiveness analysis of surveillance strategies for small, nonfunctional, radiographically benign adrenal incidentalomas. <i>Surgery</i> , 2018, 163, 197-204.	1.0	10
311	Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimerâ€™s Disease. <i>Stroke</i> , 2018, 49, 2844-2850.	1.0	9

#	ARTICLE	IF	CITATIONS
312	Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 791-803.	0.7	15
313	Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. Journal of Medical Economics, 2018, 21, 1238-1245.	1.0	80
314	Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study. Health and Quality of Life Outcomes, 2018, 16, 191.	1.0	18
315	Modelling the cost-effectiveness of pay-for-performance in primary care in the UK. BMC Medicine, 2018, 16, 135.	2.3	22
316	Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. JAMA Network Open, 2018, 1, e182008.	2.8	7
317	A Guide to the Economics of Hepatitis C Virus Cure in 2017. Infectious Disease Clinics of North America, 2018, 32, 447-459.	1.9	4
318	Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. Journal of Evaluation in Clinical Practice, 2018, 24, 772-781.	0.9	22
319	Utility elicitation in adults and children for allergic rhinoconjunctivitis and associated health states. Quality of Life Research, 2018, 27, 2383-2391.	1.5	8
320	Healthy Parent Carers programme: development and feasibility of a novel group-based health-promotion intervention. BMC Public Health, 2018, 18, 270.	1.2	27
321	Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes. Medical Decision Making, 2018, 38, 849-865.	1.2	6
322	Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value. Health Affairs, 2018, 37, 1298-1305.	2.5	6
323	Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis. PLoS Medicine, 2018, 15, e1002551.	3.9	46
324	Using Patient-Specific Quality Information to Unlock Hidden Healthcare Capabilities. Manufacturing and Service Operations Management, 2019, 21, 582-601.	2.3	22
325	Gender differences in the association between body mass index and health-related quality of life among adults:a cross-sectional study in Shandong, China. BMC Public Health, 2019, 19, 1021.	1.2	29
326	The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Global & Regional Health Technology Assessment, 2019, 2019, 228424031983852.	0.2	2
327	PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity. BMC Health Services Research, 2019, 19, 485.	0.9	17
328	The Preference of Lid Height and Laterality with an Ocular Prosthesis in Korean Patients. Journal of Korean Ophthalmological Society, 2019, 60, 308.	0.0	0
329	FDA Sodium Reduction Targets and the Food Industry: Are There Incentives to Reformulate? Microsimulation Cost-effectiveness Analysis. Milbank Quarterly, 2019, 97, 858-880.	2.1	17

#	ARTICLE	IF	CITATIONS
330	&lt;p&gt;Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States&lt;/p&gt;. Patient Preference and Adherence, 2019, Volume 13, 1375-1389.	0.8	4
331	Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention. Value in Health, 2019, 22, 1231-1239.	0.1	10
332	Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis. International Journal of Hypertension, 2019, 2019, 1-9.	0.5	8
333	Cost Effectiveness of Assessing Ultrasound Plaque Characteristics to Risk Stratify Asymptomatic Patients With Carotid Stenosis. Journal of the American Heart Association, 2019, 8, e012739.	1.6	6
334	Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk. BMC Public Health, 2019, 19, 1234.	1.2	14
335	Cost-effectiveness analysis of percutaneous mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation in Japan. Journal of Medical Economics, 2019, 22, 1312-1320.	1.0	6
336	Intracerebral hemorrhage outcome: A comprehensive update. Journal of the Neurological Sciences, 2019, 398, 54-66.	0.3	111
337	Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent Clostridioides difficile infection in US hospitals. Antimicrobial Resistance and Infection Control, 2019, 8, 17.	1.5	5
338	An economic analysis of medical and surgical management of aortopathy associated with bicuspid aortic valve. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 380-387.	1.8	3
339	Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. Pharmacoeconomics, 2019, 37, 1177-1193.	1.7	15
340	Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. Journal of Medical Economics, 2019, 22, 1243-1252.	1.0	10
341	Discrepancies between self-reported hearing difficulty and hearing loss diagnosed by audiometry: prevalence and associated factors in a national survey. BMJ Open, 2019, 9, e022440.	0.8	33
342	Health-Related Quality of Life and Its Determinants among Criminal Police Officers. International Journal of Environmental Research and Public Health, 2019, 16, 1398.	1.2	16
343	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. International Journal of Drug Policy, 2019, 72, 160-168.	1.6	23
344	Estimating Joint Health Condition Utility Values. Value in Health, 2019, 22, 482-490.	0.1	9
345	Clinical and Economic Benefits of Upper Airway Stimulation for Obstructive Sleep Apnea in a European Setting. Respiration, 2019, 98, 38-47.	1.2	13
346	Cost-Effectiveness of the US Food and Drug Administration Added Sugar Labeling Policy for Improving Diet and Health. Circulation, 2019, 139, 2613-2624.	1.6	42
347	Cost-Effectiveness Analysis of Fulvestrant 500Âmg in Endocrine Therapy-Na~ve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. Pharmacoeconomics - Open, 2019, 3, 559-570.	0.9	7

#	ARTICLE	IF	CITATIONS
348	Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. Korean Circulation Journal, 2019, 49, 252.	0.7	94
349	Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: An economic model based on the PREDICT RM database. Journal of Cardiovascular Electrophysiology, 2019, 30, 1066-1077.	0.8	17
350	Racial and Income Disparities in Health-Related Quality of Life among Smokers with a Quit Attempt in Louisiana. Medicina (Lithuania), 2019, 55, 48.	0.8	3
351	Does sex predict quality of life after acute coronary syndromes: an Australian, state-wide, multicentre prospective cohort study. BMJ Open, 2019, 9, e034034.	0.8	18
352	Comparing the needs and preferences of patients with moderate and severe dry eye symptoms across four countries. BMJ Open Ophthalmology, 2019, 4, e000360.	0.8	11
353	Long-term outcomes after operative treatment for tibial pilon fractures. OTA International the Open Access Journal of Orthopaedic Trauma, 2019, 2, e043.	0.4	18
354	Value of hospital resources for effective pressure injury prevention: a cost-effectiveness analysis. BMJ Quality and Safety, 2019, 28, 132-141.	1.8	77
355	Societal willingness to pay to avoid mortality and morbidity from Clostridioides difficile and carbapenem-resistant Enterobacteriaceae infections in the United States. American Journal of Infection Control, 2019, 47, 521-526.	1.1	3
356	How does the Cox maze procedure compare? Cost-effectiveness analysis of alternative treatments of atrial fibrillation. Current Medical Research and Opinion, 2019, 35, 957-961.	0.9	0
357	A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. Journal of Comparative Effectiveness Research, 2019, 8, 229-240.	0.6	8
358	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. Quality of Life Research, 2019, 28, 1155-1177.	1.5	9
359	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics Journal, 2019, 19, 211-218.	0.9	25
360	Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons. Clinical Infectious Diseases, 2020, 70, 1388-1396.	2.9	23
361	A bronchial airway gene expression classifier to improve the diagnosis of lung cancer: Clinical outcomes and cost-effectiveness analysis. International Journal of Cancer, 2020, 146, 781-790.	2.3	7
362	Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation. Heart Lung and Circulation, 2020, 29, 390-400.	0.2	20
363	Development and validation of the unifying elective orthopaedic score (UnEOS). A pilot study. Journal of Clinical Orthopaedics and Trauma, 2020, 11, S153-S157.	0.6	2
364	A Nationwide Study of Prevalence Rates and Characteristics of 199 Chronic Conditions in Denmark. PharmacoEconomics - Open, 2020, 4, 361-380.	0.9	50
365	Health outcome measures and determinants of using indigenous medicine in a pluralistic healthcare in Nagaland, Northeast India. Clinical Epidemiology and Global Health, 2020, 8, 205-210.	0.9	2

#	ARTICLE	IF	CITATIONS
366	Probiotics in hospitalized adult patients: a systematic review of economic evaluations. Canadian Journal of Anaesthesia, 2020, 67, 247-261.	0.7	10
367	Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. Applied Health Economics and Health Policy, 2020, 18, 533-545.	1.0	11
368	Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. American Journal of Medicine, 2020, 133, e641-e658.	0.6	5
369	Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation. Value in Health, 2020, 23, 1523-1533.	0.1	13
370	Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients. Cost Effectiveness and Resource Allocation, 2020, 18, 26.	0.6	3
371	Methods for Analysing and Reporting EQ-5D Data. , 2020, , .		125
372	Can we predict outcome after treatment of long bone osteomyelitis?. Bone and Joint Journal, 2020, 102-B, 1587-1596.	1.9	22
373	Can we predict outcome after treatment of long bone osteomyelitis?. Bone and Joint Journal, 2020, , 1-10.	1.9	0
374	Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts. Clinical Infectious Diseases, 2021, 73, e2908-e2917.	2.9	52
375	Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles. Pharmacoeconomics, 2020, 38, 1333-1343.	1.7	5
376	HTA™d in the USA: A Comparison of ICER in the United States with NICE in England and Wales. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1162-1170.	0.5	6
377	Does Screening for Depressive Symptoms Help Optimize Duloxetine Use in Knee <sc>Osteoarthritis</sc> Patients With Moderate Pain? A <sc>Cost-Effectiveness</sc> Analysis. Arthritis Care and Research, 2022, 74, 776-789.	1.5	1
378	Comparison between radiography and magnetic resonance imaging for the detection of sacroiliitis in the initial diagnosis of axial spondyloarthritis: a cost-effectiveness study. Skeletal Radiology, 2020, 49, 1581-1588.	1.2	6
380	Mapping to Quality of Life and Capability Measures in Cataract Surgery Patients: From Cat-PROM5 to EQ-5D-3L, EQ-5D-5L, and ICECAP-O Using Mixture Modelling. MDM Policy and Practice, 2020, 5, 238146832091544.	0.5	4
381	Cost-effectiveness Analysis of Screening Extremely Low Birth Weight Children for Hepatoblastoma Using Serum Alpha-fetoprotein. Journal of Pediatrics, 2020, 225, 80-89.e4.	0.9	2
382	Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. JAMA Cardiology, 2020, 5, 871.	3.0	24
383	Health Impact and Cost-Effectiveness of Volume, Tiered, and Absolute Sugar Content Sugar-Sweetened Beverage Tax Policies in the United States. Circulation, 2020, 142, 523-534.	1.6	35
384	Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 2020, 36, 145-151.	0.2	10

#	ARTICLE	IF	CITATIONS
385	Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China. <i>BMC Cancer</i> , 2020, 20, 599.	1.1	12
386	A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany. <i>Health Economics Review</i> , 2020, 10, 16.	0.8	13
387	Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?. <i>Cancers</i> , 2020, 12, 367.	1.7	15
388	Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <math>\leq 120</math> mmHg in Hypertensive Patients Without Diabetes Mellitus. <i>Value in Health Regional Issues</i> , 2020, 21, 157-163.	0.5	3
389	Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1097-1107.	0.6	2
390	Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2020, 157, 1188-1198.	0.4	21
391	Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 29-44.	1.0	7
392	Individualised selection of left-sided breast cancer patients for proton therapy based on cost-effectiveness. <i>Journal of Medical Radiation Sciences</i> , 2021, 68, 44-51.	0.8	9
393	Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 791-799.	2.2	17
394	Health State Utilities of Patients with Heart Failure: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2021, 39, 211-229.	1.7	17
395	Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 539-547.	1.3	4
396	Critical Care Beds With Continuous Lateral Rotation Therapy to Prevent Ventilator-Associated Pneumonia and Hospital-Acquired Pressure Injury: A Cost-effectiveness Analysis. <i>Journal of Patient Safety</i> , 2021, 17, 149-155.	0.7	5
397	The effects of family physician-contracted service on health-related quality of life and equity in health in China. <i>International Journal for Equity in Health</i> , 2021, 20, 15.	1.5	9
398	Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. <i>Journal of Medical Economics</i> , 2021, 24, 1060-1069.	1.0	51
399	The cost-effectiveness of schistosomiasis screening and treatment among recently resettled refugees to Canada: an economic evaluation. <i>CMAJ Open</i> , 2021, 9, E125-E133.	1.1	6
400	Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China. <i>BMC Health Services Research</i> , 2021, 21, 96.	0.9	13
401	A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
402	Utility Decrements Associated With Diabetes and Related Complications: Estimates From a Population-Based Study in Germany. <i>Value in Health</i> , 2021, 24, 274-280.	0.1	8

#	ARTICLE	IF	CITATIONS
403	Alignment, Classification, Clinical Evaluation, and Surgical Treatment for Adult Cervical Deformity: A Complete Guide. <i>Neurosurgery</i> , 2021, 88, 864-883.	0.6	20
404	Media Influence on Anxiety, Health Utility, and Health Beliefs Early in the SARS-CoV-2 Pandemicâ€”a Survey Study. <i>Journal of General Internal Medicine</i> , 2021, 36, 1327-1337.	1.3	17
405	A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. <i>Advances in Therapy</i> , 2021, 38, 1811-1831.	1.3	36
406	The effect of adherence on antihypertensive therapy plans in patients with diabetes. <i>IJSE Transactions on Healthcare Systems Engineering</i> , 2021, 11, 95-112.	1.2	1
407	Cost-effectiveness analysis of radiotherapy techniques for whole breast irradiation. <i>PLoS ONE</i> , 2021, 16, e0248220.	1.1	4
408	ACL reconstruction for all is not cost-effective after acute ACL rupture. <i>British Journal of Sports Medicine</i> , 2022, 56, 24-28.	3.1	26
409	Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective. <i>PharmacoEconomics - Open</i> , 2021, 5, 475-489.	0.9	6
410	Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management. <i>Value in Health</i> , 2021, 24, 522-529.	0.1	16
411	To ban or not to ban tanning bed use for minors: A costâ€”effectiveness analysis from multiple US perspectives for invasive melanoma. <i>Cancer</i> , 2021, 127, 2333-2341.	2.0	4
412	Disappointing Relationship between Functional Performance and Patient Satisfaction of UKA Patients: A Cross Sectional Study. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2021, 107, 102865.	0.9	15
413	Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: A Health Economic Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006789.	0.9	34
414	Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1950-1977.	0.8	8
415	Institute for Clinical and Economic Review. , 2021, , 112-141.		0
416	Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 675200.	1.1	14
417	Accuracy Requirements for Cost-effective Suicide Risk Prediction Among Primary Care Patients in the US. <i>JAMA Psychiatry</i> , 2021, 78, 642.	6.0	36
418	General population normative data for the EQ-5D-3L in the five largest European economies. <i>European Journal of Health Economics</i> , 2021, 22, 1467-1475.	1.4	22
419	Health utilities for nonâ€”melanoma skin cancers and preâ€”cancerous lesions: A systematic review. <i>Skin Health and Disease</i> , 2021, 1, e51.	0.7	5
420	Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. <i>Circulation</i> , 2021, 143, 2384-2394.	1.6	24



#	ARTICLE	IF	CITATIONS
421	Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving. <i>Surgery</i> , 2022, 171, 96-103.	1.0	5
422	Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis. <i>Health Economics Review</i> , 2021, 11, 27.	0.8	1
423	Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 929-941.	1.5	9
424	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. <i>JAMA Network Open</i> , 2021, 4, e2114501.	2.8	49
425	Economic and clinical burden of comorbidities among patients with acromegaly. <i>Growth Hormone and IGF Research</i> , 2021, 59, 101389.	0.5	10
426	Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. <i>Canadian Liver Journal</i> , 2021, 4, 360-369.	0.3	2
427	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 158-166.	0.4	7
428	Imaging of Patients Suspected of SLAP Tear: A Cost-Effectiveness Study. <i>American Journal of Roentgenology</i> , 2022, 218, 227-233.	1.0	5
429	The effect of sexual dysfunction on health-related quality of life in men following traumatic pelvic fractures. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, 91, 325-330.	1.1	6
430	Health Impact and Cost-Effectiveness of Achieving the National Salt and Sugar Reduction Initiative Voluntary Sugar Reduction Targets in the United States: A Microsimulation Study. <i>Circulation</i> , 2021, 144, 1362-1376.	1.6	17
431	Personalized Chronic Disease Follow-up Appointments: Risk-Stratified Care Through Big Data. <i>Production and Operations Management</i> , 0, , .	2.1	1
432	The effect of carpal tunnel release on health-related quality of life of 2346 patients over a 5-year period. <i>Journal of Hand Surgery: European Volume</i> , 2021, , 175319342110456.	0.5	3
433	The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon- $\beta$ 1a Therapy Versus Injectable Interferon- $\beta$ 1a Treatment in Relapsing/Remitting Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2022, 40, 91-108.	1.7	4
434	Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. <i>Expert Review of Hematology</i> , 2021, 14, 1137-1145.	1.0	3
435	Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. <i>PLoS ONE</i> , 2021, 16, e0256926.	1.1	0
436	Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. <i>BMC Health Services Research</i> , 2021, 21, 986.	0.9	13
437	Cost-Effectiveness Analysis of Hypertension Screening in the Korea National Health Screening Program. <i>Korean Circulation Journal</i> , 2021, 51, 610.	0.7	7
438	Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2028195.	2.8	48

#	ARTICLE	IF	CITATIONS
439	Utility Scores for Comorbid Conditions: Methodological Issues and Advances. , 2010, , 359-380.		4
440	Cost-Effectiveness Analysis of Stress Cardiovascular Magnetic Resonance Imaging for Stable Chest Pain Syndromes. JACC: Cardiovascular Imaging, 2020, 13, 1505-1517.	2.3	58
441	Utility-Based Quality of Life Associated With Overweight and Obesity: The Australian Diabetes, Obesity, and Lifestyle Study. Obesity, 0, , .	1.5	5
443	One-Year Quality of Life Postâ€Pneumonia Diagnosis in Japanese Adults. Clinical Infectious Diseases, 2021, 73, 283-290.	2.9	20
444	Cost-Effectiveness Analysis of Probiotic Use to Prevent Clostridium difficile Infection in Hospitalized Adults Receiving Antibiotics. Open Forum Infectious Diseases, 2017, 4, ofx148.	0.4	11
445	Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis, 2021, 32, S81-S91.	0.8	7
446	Using Patient-reported Outcome Measures to Improve Health Care. Medical Care, 2017, 55, 901-904.	1.1	25
449	The cost-effectiveness of sub-epidermal moisture scanning to assess pressure injury risk in U.S. health systems. Journal of Patient Safety and Risk Management, 2020, 25, 147-155.	0.4	17
450	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. PLoS ONE, 2011, 6, e26783.	1.1	41
451	Prevalence and Risk Factors of Chronic Otitis Media: The Korean National Health and Nutrition Examination Survey 2010â€2012. PLoS ONE, 2015, 10, e0125905.	1.1	35
452	Multivariate Meta-Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease. PLoS ONE, 2016, 11, e0152030.	1.1	19
453	Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. PLoS ONE, 2017, 12, e0169761.	1.1	65
454	Prevalence of minimal hearing loss in South Korea. PLoS ONE, 2017, 12, e0171635.	1.1	11
455	The association between observed mobility and quality of life in the near elderly. PLoS ONE, 2017, 12, e0182920.	1.1	44
456	Continuous positive airway pressure devices for the treatment of obstructive sleep apnoeaâ€hypopnoea syndrome: a systematic review and economic analysis. Health Technology Assessment, 2009, 13, iii-iv, xi-xiv, 1-119, 143-274.	1.3	172
457	Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 2010, 14, 31-8.	1.3	18
458	A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. Health Technology Assessment, 2013, 17, 1-243.	1.3	143
459	A systematic review and cost-effectiveness analysis of specialist services and adrenaline auto-injectors in anaphylaxis. Health Technology Assessment, 2013, 17, 1-117, v-vi.	1.3	21

#	ARTICLE	IF	CITATIONS
460	Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technology Assessment, 2013, 17, 1-90.	1.3	85
461	Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea/hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure. Health Technology Assessment. 2014. 18. 1-296.	1.3	43
462	Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment, 2015, 19, 1-130.	1.3	5
463	Improving the self-management of chronic pain: COping with persistent Pain, Effectiveness Research in Self-management (COPERS). Programme Grants for Applied Research, 2016, 4, 1-440.	0.4	21
464	The health impacts of energy performance investments in low-income areas: a mixed-methods approach. Public Health Research, 2018, 6, 1-182.	0.5	18
465	Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea. Yonsei Medical Journal, 2019, 60, 1157.	0.9	5
466	Postacute care model of stroke in one hospital. Tzu Chi Medical Journal, 2019, 31, 260.	0.4	3
467	Health-related quality of life in Denmark on a relative scale: mini-catalogue of mean EQ-5D-3L index scores for 17 common chronic conditions. Nordic Journal of Health Economics, 2016, 4, 44-56.	0.2	7
468	Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan. Acta Cardiologica Sinica, 2020, 36, 50-61.	0.1	9
470	Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a Spanish model-based cost effectiveness analysis. Farmacia Hospitalaria, 2013, 37, 307-16.	0.6	5
471	Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States. Clinical Therapeutics, 2021, 43, 1877-1893.e4.	1.1	6
472	Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA). Pharmacoeconomics, 2022, 40, 69-89.	1.7	7
473	Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost-Utility Analysis. Advances in Therapy, 2021, 38, 5737-5751.	1.3	4
474	A Cost-Utility Analysis of Remote Pulse-Oximetry Monitoring of Patients With COVID-19. Value in Health, 2022, 25, 890-896.	0.1	11
475	A Practical Guide to Understanding Cost-Effectiveness Analyses. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4200-4207.	2.0	7
476	Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region. Cardiovascular Diabetology, 2021, 20, 204.	2.7	13
477	Economic Costs of Diabetes and the Cost-Effectiveness of Interventions to Prevent and Control This Disease. , 2010, , 431-470.		0
479	Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis. Journal of Health Economics and Outcomes Research, 2014, 2, 131-146.	0.6	0

#	ARTICLE	IF	CITATIONS
480	The Influence of Depression on the Life Satisfaction of the Elderly with Hypertension. Journal of the Korea Society of Computer and Information, 2016, 21, 117-126.	0.0	1
481	Comparison of the Marginal Utility and Disease Burden of Hearing Loss and Other Chronic Diseases. Korean Journal of Family Medicine, 2018, 39, 364-369.	0.4	1
482	Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies. Innovations in Pharmacy, 2019, 10, 22.	0.2	2
484	Sagittal balance of the cervical spine. Journal of Orthopaedic Surgery, 2021, 29, 230949902110244.	0.4	4
485	Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region. Frontiers in Cardiovascular Medicine, 2021, 8, 750381.	1.1	25
486	Cost and Quality of Life Outcomes of the STEpped Exercise Program for Patients With Knee OsteoArthritis Trial. Value in Health, 2022, 25, 614-621.	0.1	4
487	Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics. Clinical Therapeutics, 2021, 43, 1812-1826.e7.	1.1	7
488	Analysis of EQ-5D Values. , 2020, , 61-86.		9
489	The Challenges of Living with and Caring for a Child or Children Affected by Neuronal Ceroid Lipofuscinosis Type 2 Disease: In-Depth Family Surveys in the United Kingdom and Germany. Journal of Inborn Errors of Metabolism and Screening, 0, 8, .	0.3	3
490	Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors. JAMA Network Open, 2021, 4, e2129392.	2.8	17
491	Health Inequality Analysis in Europe: Exploring the Potential of the EQ-5D as Outcome. Frontiers in Public Health, 2021, 9, 744405.	1.3	10
492	Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes mellitus. CADTH Technology Overviews, 2010, 1, e0102.	0.5	3
494	Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model. Annals of Cardiothoracic Surgery, 2012, 1, 145-55.	0.6	31
495	The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis. Ontario Health Technology Assessment Series, 2014, 14, 1-67.	3.0	12
496	Benchmarking health-related quality-of-life data from a clinical setting. American Journal of Managed Care, 2016, 22, 669-675.	0.8	1
497	Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2018, 18, 1-160.	3.0	15
498	10-kHz High-Frequency Spinal Cord Stimulation for Adults With Chronic Noncancer Pain: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2020, 20, 1-109.	3.0	3
499	Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost-effectiveness analysis. Head and Neck, 2022, 44, 431-442.	0.9	3

#	ARTICLE	IF	CITATIONS
500	Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 523-530.	0.7	11
501	Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study. <i>Advances in Therapy</i> , 2021, , 1.	1.3	8
502	Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. <i>European Journal of Health Economics</i> , 2022, 23, 807-821.	1.4	9
503	Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. <i>Thorax</i> , 2022, 77, 1079-1087.	2.7	4
504	Screening for Atrial Fibrillation in Sub-Saharan Africa: A Health Economic Evaluation to Assess the Feasibility in Nigeria. <i>Global Heart</i> , 2021, 16, 80.	0.9	2
505	Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, 1.	1.6	15
506	A Systematic Literature Review of Health Utility Values in Breast Cancer. <i>Medical Decision Making</i> , 2022, 42, 704-719.	1.2	4
508	Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers. <i>Pharmacoeconomics</i> , 2022, 40, 39-67.	1.7	9
510	Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, 9.	0.6	1
511	A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015. <i>Value in Health</i> , 2022, , .	0.1	1
512	Chronic vestibular syndromes in the elderly: Presbyvestibulopathy-an isolated clinical entity?. <i>European Journal of Neurology</i> , 2022, 29, 1825-1835.	1.7	6
513	Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 555-565.	0.5	5
514	Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. <i>Journal of Affective Disorders</i> , 2022, 308, 19-26.	2.0	11
516	Cost-effectiveness of screening for paroxysmal atrial fibrillation in patients undergoing echocardiography. <i>Internal Medicine Journal</i> , 2023, 53, 760-772.	0.5	0
517	Cost-effectiveness analysis of intensive blood pressure control in Korea. <i>Hypertension Research</i> , 2022, 45, 507-515.	1.5	3
518	Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 849474.	1.1	4
520	Priorities among effective clinical preventive services in British Columbia, Canada. <i>BMC Health Services Research</i> , 2022, 22, 564.	0.9	0
521	Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. <i>Pharmacoeconomics - Open</i> , 2022, 6, 519-537.	0.9	2

#	ARTICLE	IF	CITATIONS
522	Patient-Reported Outcomes for Function and Pain in Total Knee Arthroplasty Patients. Nursing Research, 2022, Publish Ahead of Print, .	0.8	0
523	Survivorship and Clinical Outcomes of Total Elbow Arthroplasty Using the Zimmer Nexel Elbow System. Seminars in Arthroplasty, 2022, , .	0.3	0
524	Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018. Clinical Infectious Diseases, 2023, 76, e810-e819.	2.9	8
525	Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis Study. Journal of the American Heart Association, 2022, 11, .	1.6	21
526	Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US. Pharmacoeconomics, 2022, 40, 699-714.	1.7	12
527	Development and validation of the age-associated dementia policy (AgeD-Pol) computer simulation model in the USA and Europe. BMJ Open, 2022, 12, e056546.	0.8	1
528	Cost-effectiveness of using protons for breast irradiation aiming at minimizing cardiotoxicity: A risk-stratification analysis. Frontiers in Medicine, 0, 9, .	1.2	0
529	The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial. Transplantation and Cellular Therapy, 2022, 28, 750.e1-750.e6.	0.6	10
530	An economic evaluation of knee osteoarthritis treatments in Thailand. Frontiers in Pharmacology, 0, 13, .	1.6	4
531	Estimated costs and quality-adjusted life-years lost due to N. gonorrhoeae infections acquired in 2015 in the United States: A modelling study of overall burden and disparities by age, race/ethnicity, and other factors. The Lancet Regional Health Americas, 2022, 16, 100364.	1.5	2
532	Establishment of Mono-scaled Benefit/Risk Analysis of HPV Vaccine. Yakugaku Zasshi, 2022, , .	0.0	0
533	Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated With Uveitis in the United States: A Cost-Effectiveness Analysis. Value in Health, 2022, , .	0.1	1
534	Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. Pharmacoeconomics - Open, 2023, 7, 93-110.	0.9	3
535	Catalogue of multimorbidity mean based severity and associational prevalence rates between 199+ chronic conditions- A nationwide register-based population study. PLoS ONE, 2022, 17, e0273850.	1.1	5
536	Economic Evaluation of Endoscopic versus Open Vein Harvesting. Annals of Thoracic Surgery, 2022, , .	0.7	1
537	The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis. Value in Health, 2023, 26, 216-225.	0.1	8
538	Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	15
539	Pharmacogenomic-guided clozapine administration based on HLA-DQB1, HLA-B and SLCO1B3-SLCO1B7 variants: an effectiveness and cost-effectiveness analysis. Frontiers in Pharmacology, 0, 13, .	1.6	1

#	ARTICLE	IF	CITATIONS
540	An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study. <i>Clinical Hypertension</i> , 2022, 28, .	0.7	1
541	Cost-Effectiveness of Intensive Versus Standard Blood Pressure Treatment in Older Patients With Hypertension in China. <i>Hypertension</i> , 2022, 79, 2631-2641.	1.3	1
542	Health State Utility Values of Type 2 Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis. <i>Value in Health Regional Issues</i> , 2023, 34, 14-22.	0.5	3
543	Cost-effectiveness of Compression Therapy With Early Endovenous Ablation in Venous Ulceration for a Medicare Population. <i>JAMA Network Open</i> , 2022, 5, e2248152.	2.8	3
544	Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review. <i>Pharmacoeconomics</i> , 2023, 41, 275-293.	1.7	5
545	A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction. <i>European Journal of Health Economics</i> , 2023, 24, 1441-1454.	1.4	9
546	The benefits of care: treated HIV infection and health-related quality of life among older-aged people in Uganda. <i>Aging and Mental Health</i> , 2023, 27, 1853-1859.	1.5	1
547	Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort. <i>Rheumatology</i> , 0, , .	0.9	1
548	A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers. <i>Journal of the American Society of Nephrology: JASN</i> , 2023, 34, 205-219.	3.0	2
549	Estimates of Quality-Adjusted Life-Year Loss for Injuries in the United States. <i>Medical Decision Making</i> , 0, , 0272989X2211414.	1.2	0
550	Cost-Utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. <i>Haemophilia</i> , 2023, 29, 488-497.	1.0	1
551	Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 15, 1-13.	0.7	4
552	Catalogue of socioeconomic disparities and characteristics of 199+ chronic conditionsâ€”A nationwide register-based population study. <i>PLoS ONE</i> , 2022, 17, e0278380.	1.1	4
553	Long-Term Cost-Effectiveness of Fractional Flow Reserveâ€”Based Percutaneous Coronary Intervention in Stable and Unstable Angina. , 2022, 1, 100145.		3
554	The economics of TAVI: A systematic review. <i>IJC Heart and Vasculature</i> , 2023, 44, 101173.	0.6	2
555	Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study. <i>The Lancet Regional Health Americas</i> , 2023, 19, 100427.	1.5	0
556	The Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018. <i>Journal of Infectious Diseases</i> , 2023, 227, 1007-1018.	1.9	3
557	Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19. <i>Terapevticheski Arkhiv</i> , 2023, 95, 66-77.	0.2	0

#	ARTICLE	IF	CITATIONS
558	Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial. <i>Journal of Cardiology</i> , 2023, 81, 522-530.	0.8	3
559	Cost-Effectiveness of Smoking Cessation Interventions in Patients With Ischemic Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2023, 54, 992-1000.	1.0	2
560	Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2023, 8, 419.	3.0	21
561	Effectiveness and Cost-Effectiveness of Team-Based Care for Hypertension: A Meta-Analysis and Simulation Study. <i>Hypertension</i> , 2023, 80, 1199-1208.	1.3	4
562	Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis. <i>American Journal of Epidemiology</i> , 2023, 192, 1137-1147.	1.6	3
563	The Influence of Multilevel Spinal Deformity Surgery on the EuroQol 5 Dimensions™ (EQ-5D) Questionnaire and Residential Status in the Elderly: A Prospective, Observational, Multicenter Study. <i>Global Spine Journal</i> , 0, , 219256822311625.	1.2	0
564	Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. <i>Advances in Therapy</i> , 2023, 40, 2355-2374.	1.3	2
565	Catalog of EQ-5D-3L Health-Related Quality-of-Life Scores for 199 Chronic Conditions and Health Risks in Denmark. <i>MDM Policy and Practice</i> , 2023, 8, 238146832311590.	0.5	2
590	Assessment of cervical alignment and deformity. , 2023, , 123-143.		0
591	Tobit Models. , 2023, , 7237-7242.		0